SS-31 vs MOTS-c — Mitochondria-Targeted Synthetic vs Endogenous MDP

Different classes, one organelle

The critical distinction to internalise: SS-31 is a synthetic drug you add, MOTS-c is an endogenous hormone your body already makes. They both concern mitochondria, but their intervention logic differs at the root, and that difference runs through every other comparison point below — mechanism, evidence depth, regulatory status, and research use case.

SS-31 (Chavez 2020, PNAS, PMID 32554501) is a small synthetic tetrapeptide that carries a positive charge and localises to the inner mitochondrial membrane. Its target is cardiolipin — the phospholipid that gives the inner membrane its characteristic geometry and holds electron-transport-chain complexes in the right orientation for efficient ATP production. In dysfunctional mitochondria, cardiolipin is peroxidised, the membrane geometry collapses, and ETC efficiency crashes. SS-31 physically re-stabilises this. It's structural rescue.

MOTS-c (Lee 2015, Cell Metab, PMID 25738459) is a 16-amino-acid peptide encoded within your own mitochondrial DNA, secreted into circulation, and acting on distant tissues as an endocrine signal. Its dominant systemic effect is AMPK activation in skeletal muscle and liver — improving insulin sensitivity, shifting metabolism toward oxidative phosphorylation, and acting as an exercise mimetic. It's a signalling molecule, not a structural repair.

Mechanism side-by-side

The mechanistic contrast is worth stating plainly because it is easy to conflate "both act on mitochondria" with "both act the same way." SS-31's binding target is a membrane lipid, not a receptor — Birk et al. (2013, J Am Soc Nephrol, PMID 23813215) demonstrated that SS-31 interacts directly with cardiolipin to re-energise ischaemic mitochondria, a physical, structural interaction rather than a receptor-ligand signalling event. Chavez 2020 (PMID 32554501) extended this by mapping SS-31's broader protein-interaction landscape within mitochondria, reinforcing that its site of action is localised to the organelle itself rather than mediated through a cell-surface or nuclear receptor cascade.

MOTS-c, by contrast, behaves like a hormone. It is synthesised from a mitochondrial-DNA-encoded open reading frame, exported into the cytoplasm and circulation, and acts at a distance on skeletal muscle, liver and adipose tissue via the AMPK pathway (Lee 2015, PMID 25738459). Zheng 2023 (Front Endocrinol, PMID 36761202) reviews MOTS-c's broader therapeutic-exploitation potential and reinforces that its research base is built around this endocrine signalling role — a peptide the body already produces and titrates naturally, rather than one introduced from outside.

That structural-versus-signalling distinction also explains why the two compounds have travelled such different regulatory paths: a drug that physically stabilises a defined molecular target in a defined disease context (SS-31 in Barth syndrome) is a more tractable regulatory case than an endogenous signalling peptide whose full receptor pharmacology is still under investigation (MOTS-c).

Evidence base — head-to-head vs single-arm

No published trial has tested SS-31 and MOTS-c against each other, or in combination, in humans. Every study in this page's reference list examines one compound in isolation, so any comparison here is a comparison of separate literatures, not a shared trial.

SS-31's evidence base runs from mechanistic work (Birk 2013, Chavez 2020) through to phase 2/3 clinical trials in Barth syndrome and primary mitochondrial myopathy, culminating in the 2024 FDA approval as Forzinity — the only compound discussed on this page with completed phase-3 human outcome data and a regulatory approval behind it.

MOTS-c's evidence base is earlier-stage: Lee 2015 established the metabolic phenotype in animal models and early human biomarker work, and Zheng 2023 synthesises the subsequent mechanism and therapeutic-target literature. No phase-2 or phase-3 human outcome trial for MOTS-c is included in this page's reference list. The evidence-depth gap between the two compounds is real and should inform how much weight a reader gives to claims about either one.

Clinical use cases

SS-31's only approved use case is narrow and specific: Barth syndrome, a rare genetic mitochondrial disorder, under the Forzinity indication. Research use in other mitochondrial-dysfunction contexts (age-related decline, other myopathies) remains investigational and is not covered by the Barth syndrome approval. MOTS-c has no approved use case anywhere; its research use sits within metabolic and exercise-physiology study designs — insulin sensitivity, mitochondrial biogenesis, and exercise-mimetic effects — rather than any defined patient population with a diagnosed condition.

This split roughly mirrors the broader distinction between the mitochondria-targeted synthetic peptide (MTP) class SS-31 belongs to and the mitochondrial-derived peptide (MDP) class MOTS-c belongs to — an outside-in structural drug versus an inside-out endogenous signal. A researcher deciding which compound's literature to read should start from that class-level distinction before drilling into either peptide's individual mechanism papers.

Safety signals compared

SS-31's safety profile is the better characterised of the two, by virtue of having gone through phase 2/3 clinical trials and FDA review for the Barth syndrome indication — a review process that requires a formal safety dataset in the approved population. That approved-population safety data does not automatically extend to other uses (general anti-ageing or athletic contexts), where SS-31 would be used off-label or investigationally, outside the population and dosing context the approval was based on. MOTS-c's safety data is limited to what the preclinical and early biomarker literature (Lee 2015, Zheng 2023) reports; no phase-2/3 human safety dataset is included in this page's reference list, and readers should not assume MOTS-c's safety profile has been characterised to the same standard as SS-31's Barth-syndrome dataset.

Combining them

No published trial has tested SS-31 + MOTS-c coadministration in humans. The theoretical rationale is complementary — SS-31 restores mitochondrial architecture, MOTS-c signals metabolic uplift downstream — but this is a research hypothesis, not established practice. See our SS-31 + MOTS-c cardio stack review for the current published-evidence position.

UK regulatory context

Neither is a licensed medicine in the UK. Any promotion as anti-ageing or cardio-protective products would fall under MHRA rules on advertising unlicensed medicines — see our POM advertising hub. The elamipretide FDA approval for Barth syndrome does NOT authorise UK marketing or general clinical use — MHRA has not issued a corresponding authorisation as of 2026-08, and a US FDA approval for one rare-disease indication does not extend to any other jurisdiction or use case.

Verdict / Which to choose (or neither)

This is not really a "choose one" comparison, because the two compounds are not substitutable for the same research question. SS-31 is the appropriate reference point for research into structural mitochondrial membrane repair, particularly in disease contexts resembling the Barth syndrome population it was approved for — and it is the only compound on this page with completed phase-3 human data. MOTS-c is the appropriate reference point for research into endogenous metabolic signalling, insulin sensitivity, and exercise physiology — but that literature remains preclinical and early biomarker work by comparison. Neither should be read as a general anti-ageing solution; the FDA approval for SS-31 is indication-specific, and MOTS-c has no approval anywhere. For a UK-based researcher, both compounds sit outside any domestic licensing pathway regardless of which stage of evidence each has reached in the US.

Related pages

• SS-31 monograph
• MOTS-c monograph
• Humanin monograph — endogenous cytoprotective MDP
• MOTS-c vs Humanin comparison
• SS-31 + MOTS-c cardio stack review
• Mitochondrial-derived peptides map
• Mitochondrial-derived peptides glossary entry

Verdict — research-question matching

Both address mitochondrial function but they're not competitors. SS-31 is a structural peptide that physically stabilises cardiolipin at the inner mitochondrial membrane — a drug-like pharmacological intervention with the first FDA approval (2024, Barth syndrome). MOTS-c is an endogenous signalling molecule the body already produces, whose levels decline with age. The interesting research question is whether they act synergistically (SS-31 restores mitochondrial architecture; MOTS-c signals downstream) — but no controlled study has tested that combination in humans.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

1. Birk AV, Liu S, Soong Y, et al.. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8) :1250-1261 doi:10.1681/ASN.2012121216 · PMID: 23813215
2. Chavez JD, Tang X, et al.. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020;117(26) :15363-15373 · PMID: 32554501
3. Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
4. Zheng Y, Wei Z, et al.. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14 :1120533 · PMID: 36761202